Medtronic is highlighted as a leading medical technology company with premium profit margins and consistent performance. The stock is currently undervalued, presenting a good long-term investment opportunity with a defensive profile. The analyst assigns a 'Buy' rating while noting some risks that could affect the bullish outlook. This makes Medtronic an attractive option for investors seeking diversification in the medtech sector.
The AI in orthopedic surgery market is projected to grow from $0.26 billion in 2025 to $0.87 billion by 2030, at a CAGR of 27.2%. Growth is fueled by increased orthopedic surgeries, innovations in medical imaging, adoption of minimally invasive techn...
Medtronic (MDT) menerima peringkat beli dengan target harga $92. Ini didasarkan pada panduan konservatif untuk tahun fiskal 2027 dan platform pertumbuhan yang tangguh. Perusahaan mencatat pendapatan $36,4 miliar pada tahun fiskal 2026, pertumbuhan te...
A new report reveals the surgical navigation system market, valued at $8.38 billion in 2024, is projected to grow to $18.47 billion by 2030 with a 14% CAGR. Key growth drivers include AI-guided support, augmented reality, and robotic integration, par...
Medtronic, a dividend aristocrat, currently offers a near-decade high dividend yield supported by strong revenue growth in cardiovascular and neuroscience devices. The company maintains a healthy balance sheet with a net debt to EBITDA ratio below 2x...
